News

This action allows for the initiation of clinical trials, which ContraFect expects to commence in Q1 2015. Julia P. Gregory, ContraFect’s chief executive officer commented, "CF-301 will be

The FDA Orphan Drug Designation program grants a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect less

The company will assess the efficacy and tolerability of tipifarnib as a potential new therapy for patients infected with Hepatitis Delta Virus (HDV). The Eiger BioPharmaceuticals subsidiary is

Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology. The agreement includes a guaranty with

Under the terms of agreement, Ariad will lead the completion of the Japanese new drug application (NDA) for Iclusig, while Otsuka will file the NDA for regulatory approval

The grant award will assist with advancing an SVP cancer immunotherapy from preclinical through early clinical evaluation. This immuno-oncology program is designed to develop novel SVP immunotherapies capable

With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use. GRANIX, a leukocyte growth

Undertaken at the US Army Medical Research Institute of Infectious Diseases (USAMRIID), the proof-of-concept study was focused on assessing the effect of BCX4430 treatment on survival through day

Rosacea is a common, but often misunderstood, skin disorder affecting 16 million Americans,predominantly women, ages 30 and older. Although the cause of rosacea is unknown, research suggests that